



Division of TB Elimination



Public Health Service
Centers for Disease Control
Atlanta, GA 30333

Date: 14 April 2013

To: Division Direction, Division of TB Elimination (DTBE)
NCHHSTP, OID, CDC, HHS

From: Terence Chorba, MD, DSc
Field Services and Evaluation Branch
Division of Tuberculosis Elimination/CDC

Subject: Federal TB Task Force Meeting Trip Report – Bethesda, MD

Travel Order #:

I. Purpose: To review issues concerning implementation of rapid drug resistance testing and domestic shortages of TB pharmaceuticals.

II. Dates and Place Visited:

Date(s)	Place/Person(s)
8 April	Bethesda, MD

III. Key Persons Met:

Person(s)	Title	Organization/Affiliation
Christine Sizemore, PhD	Chief, TB, Leprosy and other Mycobacterial Diseases Section	NIAID, NIH
Sarah Bur, RN, MPH	Infection Control officer	Federal Bureau of Prisons
Diana Elson, DrPH	Chief, Epidemiology	ICE, Enforcement and Removal Operations
Eileen Navarro	Acting Deputy Director	Office of Antimicrobial Products, Center for Drug Eval and Research, FDA
Mary Naughton, MD, MPH		DGMQ, NCZVED
Steven Gitterman, MD, PhD	Medical Officer	Div of Microbiology Devices, Center for Devices and Radiologic Health, FDA

IV. Key Issues, Accomplishments, Outcomes, Future Plans, and Recommendations:

Key Issues

- Advancing the development, field-testing, and registration of molecular diagnostic tests for identification of TB and drug resistance.
- Implementation of rapid drug resistance testing domestically and globally including CDC MDDR service and Xpert TB/RIF
- How can collaborations/handoffs between USG agencies be improved to expedite product development
- How can collaborations/handoffs between USG agencies be improved to expedite setting up structural entities to address issues of drug and biologic shortages.

Accomplishments

- Presented at length on issues concerning TB drug and pharmaceutical shortages. Generalized agreement was expressed that a workgroup is needed to facilitate participation of CDC, FDA, and other federal agencies in addressing this issue in a concerted, proactive fashion. DTBE/CDC, in overseeing the National TB Program's prevention and control activities, needs to consider undertaking new roles including oversight of a dashboard, warehousing, and facilitation of access to alternative sources.

Outcomes

- Discussed establishing a workgroup to develop recommendations from the Federal TB Task Force regarding mechanisms to avoid or temper future drug/pharmaceuticals shortages. Participants at the meeting recommended that the Membership or Overseers on this Work Group should include:
 - Diane Elson, ICE, Enforcement and Removal Operations
 - Brent Gibson, MD, MPH, FACPM, VP of Operations, Nat. Comm. on Correctional Health Care
 - CAPT Oliver Don Brown, ICE
 - a representative from the National Commission on Correctional Health Care (NCCHC)
 - Thomas Chiang, USAID
 - CAPT A. Martin Johnston, R.Ph., Chief, Pharmacy Logistic Support, Fed Bureau of Prisons
 - HRSA representation from the 340B Program and Perry Point
 - J. Saliba, FDA
 - NShah, T Chorba, A Cronin, S Mase, G Christie, FSEB
 - FDA Diagnostics, S. Gitterman
 - Consultancy from NTCA and Ed Zuroeste, Chief Medical Officer for Migrant Clinicians Network
 - Barbara Laughon, NIH/NIAID/DMID

Future Plans

- Slides attached to be made available to all participants from the meeting

Recommendations

- Begin implementation of the Federal TB Task Force Work Group on Drug and Pharmaceutical Shortages in making recommendations.

